Results 101 to 110 of about 742,291 (286)

Intermittent Fasting Reduces Taurine Availability and Promotes Antitumor Immunity Through PERK Attenuation‐Associated Paraptosis‐Like Cell Death in Colorectal Cancer

Advanced Science, EarlyView.
This study identifies reduced taurine availability as a mediator of intermittent fasting in colorectal cancer and shows that taurine interacts with GRP78 to maintain PERK abundance post‐transcriptionally. It further shows that taurine depletion destabilizes PERK, induces immunogenic paraptosis, remodels the tumor microenvironment toward a CD8+ T cell ...
Baohui Song, Sikei Kam, Jingyi Liu, Rui Lv, Xucheng Huo, Zhanghan Chen, Yuelun Dong, Shilun Cai, Bing Li, Ruobing Ren, Yunshi Zhong, Mingyan Cai   +11 more
wiley   +1 more source

Novel PARP inhibitors sensitize human leukemic cells in an endogenous PARP activity dependent manner

, 2016
Poly(ADP-ribose) polymerase (PARP) is a critical nuclear enzyme which safeguards genome stability from genotoxic insults and helps in DNA repair. Inhibition of PARP results in sustained DNA damage in cancer cells.
Swarup, Hassan A., Pavankumar, Chottanahalli S., Raghavan, Sathees C., Swarup, Hassan A, Qamar, Imteyaz, Pavan Kumar, C. S., Swarup, H. A., Hegde, Mahesh, Mantelingu, K., Raghavan, S. C., Rangappa, Kanchugarakoppal S., Mantelingu, Kempegowda, Rangappa, K. S., Pavankumar, Chottanahalli S, Raghavan, Sathees C, Rangappa, Kanchugarakoppal S   +15 more
core   +1 more source

Mitochondrial Localization of Cx26 Promotes Colorectal Cancer Malignancy and Exposes a Fatal Vulnerability to Drug Targeting

Advanced Science, EarlyView.
Mitochondrial localization of Cx26 emerges as a double‐edged sword in colorectal cancer. PIMT‐mediated methylation of Cx26 promotes its mitochondrial localization and stability. Mitochondrial Cx26 then facilitates ER‐mitochondria communication and Ca2+ signaling, thereby promoting metastatic progression. Bortezomib exploits this malignant adaptation by
Jie Wang, Lu Chen, Jia Qin, Xiaoning Wang, Sunlan Ye, Ning An, Mei Bai, Yan Shen, Xuefeng Wu, Qiang Xu   +9 more
wiley   +1 more source

Lactate‐H3K18la‐RPL11 Axis Drives Gemcitabine Resistance in Pancreatic Cancer by Integrating Protein Synthesis and DNA Damage Repair

Advanced Science, EarlyView.
A lactate‐H3K18la epigenetic axis upregulates RPL11 to drive gemcitabine resistance in pancreatic cancer. RPL11 orchestrates chemoresistance through a dual, compartmentalized role: enhancing cytoplasmic protein synthesis via EEF1A1 stabilization and promoting nuclear DNA damage repair by co‐activating PARP14, thus ensuring robust cell survival ...
Lijun Zhao, Jianzhong Cao, Wenyue Liu, Xuyun Li, Haolin Zhang, Xiaofang Zhang, Shiyang Shi, Huilong Yin, Junjie Li, Angang Yang, Rui Zhang   +10 more
wiley   +1 more source

Mechanism‐Informed Language Modeling and Oxygenated 3D Screening Identify Berberine–Enzalutamide Synergy in Prostate Cancer Models

Advanced Science, EarlyView.
By integrating knowledge‐augmented artificial intelligence with an oxygen‐supplemented 3D screening platform, a synergistic interaction between berberine and enzalutamide is identified. The framework integrates compound mechanisms of action with disease‐relevant signaling context to prioritize candidate combinations and generate testable pathway‐based ...
Chih‐Hui Lo, Katie Shi, Lina Kafadarian, Alexandra Bermudez, Johnny Diaz, Liam Edwards, Yunqi Hong, Ziyi Chen, Hyeonji Hwang, Weihong Yan, Alan Levinson, Robert Damoiseaux, Cho‐Jui Hsieh, Tanya Stoyanova, Andrew S. Goldstein, Neil Y.C. Lin   +15 more
wiley   +1 more source

On the Way to Selective PARP‐2 Inhibitors. Design, Synthesis, and Preliminary Evaluation of a Series of Isoquinolinone Derivatives

, 2008
PARP-1 and PARP-2 are members of the family of poly(ADP-ribose)polymeroses, which are involved in the maintenance of genomic integrity under conditions of genotoxic stimuli. The different roles of the two isoforms under pathophysiological conditions have
Flavio Moroni, Chiarugi, Alberto, Roberto Pellicciari, Camaioni, Emidio, Alberto Chiarugi, EREN, GÖKÇEN, Venturoni, Francesco, Bellocchi, Daniele, Paola Sabbatini, Pellicciari, Roberto, Gabriele Costantino, Francesco Venturoni, Sabbatini, Paola, Emidio Camaioni, Daniele Bellocchi, Formentini, Laura, Laura Formentini, Costantino, Gabriele, Moroni, Flavio, Gökçen Eren   +19 more
core   +2 more sources

The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings

Molecular Oncology, 2011
Poly (ADP‐ribose) polymerase (PARP) inhibitors effectively kill tumours defective in the BRCA1 or BRCA2 genes through the concept of synthetic lethality. It is suggested that PARP inhibitors cause an increase in DNA single‐strand breaks (SSBs), which are
Thomas Helleday
doaj   +1 more source

Sensitizing HR-proficient cancers to PARP inhibitors

, 2017
Breast cancer is a heterogeneous disease, manifesting in a broad differentiation in phenotypes and morphologic profiles, resulting in variable clinical behavior. Between 10 and 20% of all breast cancers are triple negative. Triple-negative breast cancer (
Elgene Lim, Violeta Serra, Lim, E., Shapiro, G., Shawn F. Johnson, Geyer, M., Matthias Geyer, Serra, V., Geoffrey I. Shapiro, Johnson, S.   +9 more
core   +1 more source

Low‐Density Lipoprotein Receptor‐Targeted Biomimetic Nanoplatform Suppresses Glioblastoma Stemness and Remodels Antitumor Immunity via Dual Metabolic Disruption

Advanced Science, EarlyView.
A low‐density lipoprotein receptor‐oriented biomimetic nanoplatform couples brain‐tumor delivery with a mechanistically matched regorafenib‐erythrodiol combination. Concurrent disruption of autophagic nutrient salvage and cholesterol homeostasis collapses bioenergetic and signaling support, suppresses glioblastoma stemness, and promotes immunogenic ...
Yining Jiang, Wenzhuo Yang, Wenting Cheng, Jing Zuo, Lin Pan, Sheng Zhong, Ren Geng, Yao Zhao, Zijian Chen, Canhua Huang, Yang Bai, Liyan Zhao, Yunqian Li   +12 more
wiley   +1 more source

PARP Inhibitors as a Novel Treatment Strategy for Patients with BRCA-Mutated Metastatic Breast Cancer

European Medical Journal Oncology, 2019
Inhibitors of poly(ADP-ribose) polymerase (PARP), such as olaparib and talazoparib, have recently been approved as therapies for BRCA-mutated human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (BC).
Katarzyna Rygiel
doaj